🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
GlaxoSmithKline
Phase 2
307
Bradford, London, Newcastle upon Tyne
2025-02-10
Recruiting
Real World Evaluation of Lifelight®: A Contactless Vital Signs Monitor for Self-monitoring Blood Pressure and Its Comparison to Standard of Care
NCT06325384Hypertension
Xim Limited
Not applicable
500
London
2025-02-10
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
London
2025-02-07
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London
2025-02-06
Active, closed
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239Systemic Sclerosis (SSc), Scleroderma
Zura Bio Inc
Phase 2
80
Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent
2025-02-06
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
216
Wigan, London, Taunton
2025-02-06
By invitation
Use of TrachPhone in Tracheostomized Patients
NCT06487104Tracheostomy
Atos Medical AB
Not applicable
22
London
2025-02-05
Recruiting
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
NCT06809686Heart Failure
Richmond Research Institute
Observational
1,000
London
2025-02-05
Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Maze Therapeutics
Phase 2
74
Leicester, London
2025-02-05
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
Bristol-Myers Squibb
Phase 1/2
416
London, Glasgow, Birmingham, Newcastle upon Tyne
2025-02-04
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc.
Phase 3
320
Bristol, Cambridge, London, Newcastle
2025-02-03
Recruiting
A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine
NCT06772025Cardiac Surgery-associated Acute Kidney Injury
Bayer
Not applicable
200
Cambridge, Harefield, London
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Basingstoke, Colney, London
2025-02-03
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.
Phase 3
170
Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth
2025-02-01
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
Rigel Pharmaceuticals
Phase 2
60
London
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Derriford, London, Oxford, Southampton
2025-01-30
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
Definium Therapeutics US, Inc.
Phase 3
245
Glasgow, Gosforth, London, Manchester, Sheffield
2025-01-29
By invitation
Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment
NCT06726122Skin Laxity, Wrinkle, Skin Condition
Candela Corporation
Not applicable
60
Kings Hill, London
2025-01-28
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester
2025-01-28
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
Epkin
Phase 1
146
Glasgow, Leicester, London, Manchester, Oxford
2025-01-23
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
Incyte Corporation
Phase 3
240
Bristol, Glasgow, London, Manchester, Nottingham, Plymouth
2025-01-21
Recruiting
Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging
NCT06639828Focal Liver Lesions
GE Healthcare
Phase 4
50
Bristol, London
2025-01-20
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
London, Newcastle upon Tyne, Dundee, Harrow
2025-01-17
Active, closed
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
Janssen Research & Development, LLC
Phase 1
64
Cambridge, London, Manchester
2025-01-14
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
Immatics US, Inc.
Phase 3
360
Cambridge, Glasgow, London, Manchester, Oxford, Southampton
2025-01-14
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
London, Manchester, Sheffield
2025-01-10
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462Rheumatoid Arthritis
Immunovant Sciences GmbH
Phase 2
120
Edinburgh, London, North Shields, Wolverhampton
2025-01-10
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Harlow, Truro, Maidstone, Taunton, Sutton, Coventry, Guildford, London
2025-01-06
By invitation
Evaluating Non-Invasive Haptics During Extreme Exercise
NCT07285252VO2max, Lactate Threshold, Lactate
SuperPatch Limited LLC
Not applicable
75
London
2025-01-05
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 2
249
Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Maidstone
2025-01-03
Recruiting
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
NCT06769633Duchenne Muscular Dystrophy
Italfarmaco
Phase 2
18
Leeds, London, Newcastle upon Tyne, Oxford
2025-01-02
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
Takeda
Phase 3
396
London, Edinburgh, Glasgow
2025-01-02
Recruiting
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
NCT05098665Cardiac Amyloidosis
Richmond Research Institute
Not applicable
320
London
2025-01-01
Recruiting
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
NCT06514612Acquired Blepharophimosis
Santen SAS
Phase 3
234
Leeds, London, Sunderland
2024-12-30
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
Cambridge, London
2024-12-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
Janssen Research & Development, LLC
Phase 1
120
Leicester, London, Plymouth
2024-12-30
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830Treatment Resistant Depression
atai Therapeutics, Inc.
Phase 2
142
Doncaster, London, Motherwell
2024-12-30
Recruiting
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
NCT06805695Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
iECURE, Inc.
Observational
13
London
2024-12-23
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
32
London
2024-12-20
Active, closed
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Observational
401
Birmingham, London, Newcastle upon Tyne, Sheffield
2024-12-19
Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Amryt Pharma
Observational
580
London
2024-12-18
Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3
280
Liverpool, London
2024-12-17
Recruiting
Ixovex-1 Single Agent and Combination Therapy
NCT06549946Solid Tumor, Head and Neck Cancer
Psivac Ltd
Phase 1/2
18
London
2024-12-17
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals
Phase 2
21
Sheffield, London
2024-12-17
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
480
Greater London, Liverpool, London, Manchester, Sutton, Torquay
2024-12-16
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc.
Observational
75
London
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
London
2024-12-16
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
Arcus Biosciences, Inc.
Phase 3
610
Birmingham, Cottingham, London, Manchester
2024-12-13
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
AbbVie
Phase 2
185
London, Oxford, Birmingham, Dundee
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Hull, Leeds, London, Northwood
2024-12-12
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
GlaxoSmithKline
Phase 3
514
Leeds, London
2024-12-12
Active, closed
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
NCT06681324Crohn's Disease
AstraZeneca
Phase 2
24
Birmingham, Cambridge, London
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
350
Leicester, Llanrhystud, London, Peterborough, Stockport, Wolverhampton
2024-12-11
Active, closed
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
BioInvent International AB
Phase 1/2
35
London, Cardiff, Manchester
2024-12-11
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
Headington, Edinburgh, London
2024-12-11
Recruiting
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT06669247Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2
186
London, Manchester
2024-12-11
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cambridge, Exeter, London, Newcastle upon Tyne
2024-12-11
Recruiting
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
NCT06667453Myotonic Dystrophy 1
PepGen Inc
Phase 2
24
Salford, London, Cardiff, Newcastle upon Tyne
2024-12-10
Recruiting
DERMATOMICS: Identifying Regulators of Skin Homeostasis
NCT06894654Systemic Sclerosis (SSc)
Relation Therapeutics
Observational
500
Leeds, London
2024-12-10
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3
707
Glasgow, London, Sutton
2024-12-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
Hoffmann-La Roche
Phase 2
62
Exeter, London
2024-12-09
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals
Phase 3
60
West Midlands, London
2024-12-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Birmingham, Exeter, London, Manchester, Oxford
2024-12-09
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886Hematologic Malignancies, Adult
Kumquat Biosciences Inc.
Phase 1
13
London, Nottingham
2024-12-09
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
London
2024-12-06
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon
2024-12-04
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London
2024-12-04
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
700
Bellshill, Birmingham, Cardiff, Hexham, London, Manchester
2024-12-03
Active, closed
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622Multiple System Atrophy
H. Lundbeck A/S
Phase 3
401
Salford, Oxford, Glasgow, Newcastle upon Tyne, Exeter, London
2024-12-03
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Recruiting
Avapritinib Rollover Study
NCT06748001Mastocytosis, Systemic
Blueprint Medicines Corporation
Phase 4
60
London
2024-11-28
Active, closed
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396Metastatic Breast Cancer
Merck Sharp & Dohme LLC
Phase 2
120
Truro, London, Withington, Ipswich
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
EyePoint Pharmaceuticals, Inc.
Phase 3
400
London
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
London, Manchester, Norwich, Nottingham, Plymouth
2024-11-27
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Recruiting
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281Crohn Disease, Colitis, Ulcerative
Merck Sharp & Dohme LLC
Phase 3
1,380
London, Prescot
2024-11-25
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab
Phase 3
191
Glasgow, London, Manchester, Nottingham, Plymouth
2024-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
2024-11-21
Active, closed
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667Neovascular Age-related Macular Degeneration
Sanofi
Phase 1/2
66
London, Liverpool
2024-11-21
Active, closed
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
50
Cardiff, Leeds, Liverpool, London, Southampton
2024-11-21
Recruiting
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
NCT06498128Insomnia
Idorsia Pharmaceuticals Ltd.
Observational
785
London
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
Daiichi Sankyo
Phase 3
700
Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay
2024-11-19
By invitation
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT06435312Generalized Myasthenia Gravis
UCB Biopharma SRL
Phase 3
8
Glasgow, London
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Recruiting
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378Chronic Granulomatous Disease (CGD)
Ensoma
Observational
60
London
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587Solid Tumor
Genentech, Inc.
Phase 1
410
Edinburgh, London, Manchester, Sutton
2024-11-14
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Leeds, London, Luton
2024-11-11
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
GlaxoSmithKline
Phase 2
283
London, Middlesbrough
2024-11-11
Active, closed
A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
NCT06713135Duchenne Muscular Dystrophy
Santhera Pharmaceuticals
Phase 4
80
Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle
2024-11-10
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
Recruiting
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
NCT06663358Fabry Disease
Chiesi Farmaceutici S.p.A.
Observational
100
Edgbaston, Salford, London
2024-11-06
Recruiting
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993Von Willebrand Disease (VWD)
Takeda
Phase 3
24
London, Oxford
2024-11-06
Active, closed
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
NCT06647407Meningococcal Immunization, Healthy Volunteers
Sanofi Pasteur, a Sanofi Company
Phase 1/2
750
Exeter, London, Southampton
2024-11-05
Recruiting
First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System
NCT06423690Lung Cancer
Snipe Medical
Not applicable
15
London
2024-11-01
Rows per page Showing 601–700 of 2005
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=7

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.